E
Elizabeth H. Stover
Researcher at Harvard University
Publications - 48
Citations - 5226
Elizabeth H. Stover is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 18, co-authored 40 publications receiving 3961 citations. Previous affiliations of Elizabeth H. Stover include Broad Institute & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools,Jan Cools,Daniel J. DeAngelo,Jason Gotlib,Elizabeth H. Stover,Robert D. Legare,Robert D. Legare,J. E. Cortes,Jeffrey L. Kutok,Jennifer J. Clark,Ilene Galinsky,James D. Griffin,Nicholas C.P. Cross,Ayalew Tefferi,James M. Malone,Rafeul Alam,Stanley L. Schrier,Janet L. Schmid,Michal G. Rose,Peter Vandenberghe,Gregor Verhoef,Marc Boogaerts,Iwona Wlodarska,Hagop M. Kantarjian,Peter Marynen,Steven Coutre,Richard Stone,D. Gary Gilliland +27 more
TL;DR: The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
Journal ArticleDOI
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.
Robert M. Bachoo,Elizabeth A. Maher,Keith L. Ligon,Norman E. Sharpless,Suzanne S Chan,Mingjian James You,Yi Tang,Jessica DeFrances,Elizabeth H. Stover,Ralph Weissleder,David H. Rowitch,David N. Louis,Ronald A. DePinho +12 more
TL;DR: These data support the view that dysregulation of specific genetic pathways, rather than cell-of-origin, dictates the emergence and phenotype of high-grade gliomas and provide evidence that p16(INK4a) and p19(ARF) synergize to maintain terminal astrocyte differentiation.
Journal ArticleDOI
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt,Sachet A. Shukla,Lynette M. Sholl,Lauren L. Ritterhouse,Jaclyn C Watkins,Scott J. Rodig,Elizabeth H. Stover,Kyle C. Strickland,Alan D. D'Andrea,Catherine J. Wu,Catherine J. Wu,Ursula A. Matulonis,Panagiotis A. Konstantinopoulos +12 more
TL;DR: Polymerase e-mutated and MSI ECs are associated with high neoantigen loads and number of TILs, which is counterbalanced by overexpression of PD-1 and PD-L1, which may be excellent candidates forPD-1-targeted immunotherapies.
Journal ArticleDOI
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Liya Ding,Hye-Jung Kim,Qiwei Wang,Michael Kearns,Tao Jiang,Carolynn E. Ohlson,Ben Li,Shaozhen Xie,Joyce F. Liu,Elizabeth H. Stover,Brooke E. Howitt,Roderick T. Bronson,Suzan Lazo,Thomas M. Roberts,Gordon J. Freeman,Panagiotis A. Konstantinopoulos,Ursula A. Matulonis,Jean J. Zhao,Jean J. Zhao +18 more
TL;DR: It is found that PARP inhibition by olaparib triggers robust local and systemic antitumor immunity involving both adaptive and innate immune responses through a STING-dependent antitumors immune response in mice bearing Brca1-deficient ovarian tumors.
Journal ArticleDOI
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Michal Slyper,Caroline B. M. Porter,Orr Ashenberg,Julia Waldman,Eugene Drokhlyansky,Isaac Wakiro,Isaac Wakiro,Christopher Smillie,Gabriela Smith-Rosario,Jingyi Wu,Jingyi Wu,Danielle Dionne,Sébastien Vigneau,Sébastien Vigneau,Judit Jané-Valbuena,Timothy L. Tickle,Sara Napolitano,Sara Napolitano,Mei-Ju Su,Mei-Ju Su,Anand G. Patel,Asa Karlstrom,Simon Gritsch,Masashi Nomura,Avinash Waghray,Satyen H. Gohil,Satyen H. Gohil,Alexander M. Tsankov,Alexander M. Tsankov,Livnat Jerby-Arnon,Ofir Cohen,Ofir Cohen,Johanna Klughammer,Yanay Rosen,Joshua Gould,Lan Nguyen,Matan Hofree,Peter J. Tramontozzi,Bo Li,Bo Li,Catherine J. Wu,Benjamin Izar,Rizwan Haq,Rizwan Haq,F. Stephen Hodi,Charles H. Yoon,Charles H. Yoon,Aaron N. Hata,Suzanne J. Baker,Mario L. Suvà,Mario L. Suvà,Raphael Bueno,Elizabeth H. Stover,Elizabeth H. Stover,Michael R. Clay,Michael A. Dyer,Michael A. Dyer,Natalie B. Collins,Natalie B. Collins,Natalie B. Collins,Ursula A. Matulonis,Nikhil Wagle,Bruce E. Johnson,Asaf Rotem,Asaf Rotem,Orit Rozenblatt-Rosen,Aviv Regev,Aviv Regev,Aviv Regev +68 more
TL;DR: A set of ready-to-use tools for profiling fresh and frozen clinical tumor samples using scRNA-Seq and snRNA- Seq facilitates the implementation of single-cell technologies in clinical settings and the construction ofsingle-cell tumor atlases.